时间标签：数据日期 2026-10-31 · 生成时间 2026-11-01 05:30（Asia/Shanghai）｜ 检索窗口 PubMed edat 2026/10/28–2026/10/31 ｜ 情报发生日期 2026-10-31
研究问题
These class-specific biological effects provide a rationale for investigating whether systemic glucose-lowering therapy is associated with differences in periodontal or peri-implant outcomes.；However, evidence regarding the relationship between systemic glucose-lowering therapy and periodontal or peri-implant outcomes has not been comprehensively synthesised across medication classes.；Existing systematic reviews have generally examined individual drug classes, particularly GLP-1RAs, evaluated local drug delivery as an adjunct to periodontal therapy, or focused on whether periodontal treatment improves glycaemic control.
方法
Eligible designs were randomised or non-randomised interventional studies and analytic observational studies.；Risk of bias was assessed using the RoB 2 tool [] for randomised trials and the Newcastle-Ottawa Scale (NOS) for observational studies [].；Because the included studies differed substantially in drug classes, comparators, study designs, follow-up periods, and outcome measures, quantitative synthesis was not performed.
核心结论
Persistent hyperglycaemia can promote periodontal tissue destruction through mechanisms, including impaired immune responses, increased oxidative stress, accumulation of advanced glycation end products, and dysregulated inflammatory pathways.；Different classes of glucose-lowering medications have distinct biological effects that may influence periodontal tissues, bone metabolism, inflammation, and immune responses.；Metformin has been associated with anti-inflammatory and potential osteogenic effects, while thiazolidinediones can modulate inflammatory pathways and bone metabolism. ‖ 结论：Well-designed prospective studies and randomised controlled trials using standardised periodontal and peri-implant outcomes are needed to clarify these associations.
局限
Evidence linking systemic glucose-lowering therapies with periodontal and peri-implant outcomes in adults with T2DM remains limited, heterogeneous, and predominantly observational.；Although preliminary findings suggest potentially favourable periodontal effects of incretin-based therapies, the available evidence is insufficient to establish causality or support clinical recommendations.
对本项目的价值
★☆☆☆☆ 代谢轴既干预敏感性最高，也是老药新用供给最充足的来源。设计 cross-sectional、prospective cohort、randomised controlled trial。
全文来源
PMC JATS 全文（正文 15,399 字符，已过标题/DOI 逐字归属校验）
原文题录
- 英文标题：Systemic Glucose-Lowering Therapies and Periodontal and Peri-Implant Outcomes in Adults With Type 2 Diabetes Mellitus: A Systematic Review.
- 期刊与标识：Cureus · PMID 42948780 · DOI 10.7759/cureus.117011
C 级证据分级：C 级（预印本 / 观点评论，非原始研究）
本文属观点/评论类文献，不是原始研究。其论点依赖于作者对既有证据的梳理与判断，不构成新的实验证据。本站标注 C 级即为此意——阅读时请把它当作「领域内的思考框架」，而非「研究发现」。
关于本文的文献来源：本站依据 IMA 知识库「五刊监控·深度文献卡片」撰写，依据已获取的期刊全文（方法、样本量与结论已回到原文核对）；未能获取全文的同批条目另行标注「摘要级」，全程未做任何数值推算补全。